PMC4168986_01
Graphical representation of tumor marker and alkaline phosphatase over time. A: Tumor marker CA 27-29 levels after each treatment with radium-223 (Ra-223) dichloride, B: Serial alkaline phosphate (ALP) levels after each treatment with Ra-223 dichloride.
2162-3619-3-23-1.jpg
PMC4168986_01_2162-3619-3-23-1.jpg
F1
Figure 1 shows a graphical representation of the decreases in CA27-29 (A) and alkaline phosphate levels (B).
Imaging study with 18F-FDG PET/CT. A: 18F-FDG PET/CT imaging studies at baseline, before administration of radium-223 (Ra-223) dichloride, B: 8F-FDG PET/CT imaging studies after 2 treatments with Ra-223 dichloride but before the third treatment.
2162-3619-3-23-2.jpg
PMC4168986_01_2162-3619-3-23-2.jpg
F2
For the sake of this report, 2 index lesions were selected for analysis on the 18F-FDG PET/CT (Figure 2) and 18F-NaF bone PET/CT (Figure 3) imaging studies.
Imaging study with 18Na-F Bone PET/CT. A: 18NA-F bone PET/CT imaging studies at baseline, before administration of radium-223 (Ra-223) dichloride, B: 8NA-F bone PET/CT imaging studies after 2 treatments with Ra-223 dichloride but before the third treatment.
2162-3619-3-23-3.jpg
PMC4168986_01_2162-3619-3-23-3.jpg
F3
For the sake of this report, 2 index lesions were selected for analysis on the 18F-FDG PET/CT (Figure 2) and 18F-NaF bone PET/CT (Figure 3) imaging studies.